Chengdu Suncadia Medicine Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-19
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING1
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HRS-3095 Tablet NCT07613866 |
P2 | Not yet recruiting | Chronic Spontaneous Urticaria | 190 | 2026-12 |
| HRS-5965 NCT07014826 |
P3 | Active, not recruiting | Primary IgA Nephropathy | 389 | 2027-10 |
| HRS-5965 tablets NCT06238544 |
P2 | Active, not recruiting | Paroxysmal Nocturnal Hemoglobinuria | 132 | 2027-12 |
| HRS-5965 Capsules NCT07582133 |
P2 | Recruiting | Primary IgA Nephropathy | 380 | 2029-07 |
| HRS-9308 Tablet NCT07940439 |
P1/2 | Not yet recruiting | Solid Tumor | 126 | 2030-12 |